IndustryCompany release

Rhythm posts $92.1M Q3 IMCIVREE sales, secures up to $750M loan

🇺🇸 Rhythm Pharmaceuticals, Inc. (RYTM) · Tue 03 Nov 2026

Rhythm Pharmaceuticals reports 29% quarterly growth for IMCIVREE after its US hypothalamic obesity launch, alongside a cheaper bivamelagon licence deal and a new term loan.

Rhythm Pharmaceuticals reported third-quarter 2026 results on 3 November, with global net revenue from IMCIVREE (setmelanotide) of $92.1M. The company said this was 29% higher than in the previous quarter.

It attributed the growth to the US launch in acquired hypothalamic obesity, an indication the FDA approved on 19 March 2026. Rhythm also said it has begun the launch of IMCIVREE in Japan.

On financing, Rhythm has secured a five-year term loan of up to $750M, led by HealthCare Royalty with Blackstone. Separately, it amended its licence agreement with LG Chem for bivamelagon: $350M in fixed payments over four years will reduce the royalty on the product to 1%.

Bivamelagon is moving into pivotal trials in acquired hypothalamic obesity and in Prader-Willi syndrome, according to the company.

What it means for your team

  • The first full commercial quarters after the March FDA approval in acquired hypothalamic obesity are now feeding through, so payer and access activity in this indication is likely to stay in focus.
  • The Japan launch adds a further market where post-marketing and local pharmacovigilance obligations will apply to IMCIVREE.
  • Pivotal programmes for bivamelagon in two indications point to future regulatory filings, though no timelines were given in the information available.
  • The reduced royalty and new loan reshape the company's financial position for its pipeline; teams tracking partners or competitors in rare obesity may wish to note this.

Company's press release (SEC filing): Rhythm Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Rhythm Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →